Minimally-Invasive Toxicity Assessment via Molecular Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional preclinical toxicology studies using histopathological analyses are cumbersome, time-intensive, and costly, prone to sampling errors, and often detect toxicity too late in the drug discovery process, leading to significant resource loss and termination of drug programs.
Innovation Solution
A minimally-invasive whole-body scanning method using molecular imaging agents like 99mTc-duramycin, which binds to markers of apoptosis and necrosis, allowing for non-invasive detection of toxicity-induced tissue injury through techniques such as PET, SPECT, and MRI, providing a systemic and dynamic assessment of drug toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If histopathological analyses using excised tissues are used, then toxicity detection accuracy is improved, but time consumption and cost increase significantly
Solution Approach 1:
The patent replaces the mechanical histopathological analysis system (excised tissue examination) with a molecular imaging system using radiotracers and imaging devices (PET/SPECT). This substitution enables non-invasive, real-time toxicity detection without requiring tissue excision and laboratory processing, thereby dramatically reducing time consumption while maintaining detection accuracy.
Solution Approach 2:
The patent creates a functional copy of histopathological detection capabilities through molecular imaging. By using radiotracers that bind to specific toxicity markers (such as phosphatidylethanolamine in apoptotic cells), the imaging system reproduces the toxicity detection function of histopathology in a non-invasive, whole-body format, eliminating the need for physical tissue sectioning and microscopic examination.
2Measurement precision
If histopathological analyses using excised tissues are used, then toxicity detection accuracy is improved, but operational complexity and cost increase
Solution Approach 1:
The patent replaces the complex mechanical histopathological workflow (tissue excision, fixation, sectioning, staining, microscopic examination) with a simplified molecular imaging workflow (radiotracer injection, imaging scan, image analysis). This substitution dramatically reduces operational complexity while maintaining toxicity detection accuracy, making the process more accessible and easier to perform.
3Measurement precision
If histopathological analyses are performed, then sampling errors are reduced, but the process becomes more time-intensive
Solution Approach 1:
The patent transitions from two-dimensional histological section examination to three-dimensional whole-body molecular imaging. This dimensional change allows simultaneous visualization of toxicity across multiple organs and tissues in their spatial context, eliminating sampling errors inherent in section-based analysis while providing comprehensive toxicity assessment in a single evaluation.
Solution Approach 2:
The patent merges multiple histopathological evaluations into a single molecular imaging study. By using radiotracers that accumulate in toxic lesions throughout the body, the imaging process combines what would otherwise require multiple separate tissue samples and examinations into one non-invasive, whole-body assessment, reducing both time and sampling variability.
4Measurement precision
If toxicity is detected at late stage in drug discovery, then accurate toxicity assessment is achieved, but resource loss and program termination occur
Solution Approach 1:
The patent enables preliminary toxicity assessment using molecular imaging at early stages of drug development, before committing extensive resources to later-stage trials. By detecting toxicity signals early through non-invasive imaging, problematic candidates can be identified and eliminated upfront, preventing waste of time and resources on doomed programs while maintaining accurate toxicity detection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early and accurate detection of toxicity-induced tissue injury, reducing resource loss by providing real-time, individualized toxicity profiles, accelerating decision-making in drug discovery and development, and minimizing sampling errors, while being applicable to various therapeutic drugs beyond chemotherapeutics.
Implementation Method 1
a binding moiety that binds to a marker of toxicity-induced tissue injury
Implementation Method 2
the detectable moiety comprises a metal ion, stable isotope, or radionuclide
Implementation Method 3
performing a molecular imaging scan of the subject
Implementation Method 4
detecting the marker of toxicity-induced tissue injury within the subject
Data Source
AI summary
Provided herein are compositions, systems, and methods for minimally-invasive assessment of toxicity-induced tissue injury. In particular, external (e.g., whole-body) scanning is employed to detect toxicity-induced injuries, such as those caused by chemotherapeutics.